Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)
HPV and Gynecologic Cancer
Related content
HPV and Gynecologic CancerEndometriosis
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
Br J Cancer.
Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group
doi: 10.1038/s41416-018-0310-8.
Uro-Oncology
Identifying the candidate for super extended staging pelvic lymph node dissection among patients with high-risk prostate cancer
BJU Int.
Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Mazzone E, Dell'Oglio P, Stabile A, Freschi M, Montorsi F, Briganti A
doi: 10.1111/bju.14066.
Uro-Oncology
Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer
J Urol.
Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW, Chapin BF
doi: 10.1097/JU.0000000000001074.
Overactive BladderUro-Oncology
Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer
Int J Urol.
Kobatake K, Hayashi T, Black PC, Goto K, Sentani K, Kaneko M, Yasui W, Mita K, Teishima J, Matsubara A
doi: 10.1111/iju.13389.
Uro-Oncology
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer
Prostate Cancer Prostatic Dis.
Preisser F, Gandaglia G, Arad F, Karakiewicz PI, Bandini M, Pompe RS, Montorsi F, Graefen M, Huland H, Briganti A, Tilki D
doi: 10.1038/s41391-020-00266-4.
Uro-Oncology
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921
J Clin Oncol.
Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W1, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM
doi: 10.1200/JCO.2017.76.4126.
Uro-Oncology
Radical Prostatectomy or Radiotherapy for High and Very High Risk Prostate Cancer: A Multidisciplinary Clinic Experience of Patients Eligible for Either Treatment
BJU Int.
Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF
doi: 10.1111/bju.14780.
HPV and Gynecologic Cancer
Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers
Cancer Epidemiol Biomarkers Prev.
Glubb DM, Thompson DJ, Aben KK, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjørge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Bützow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen X, Chen Z, Cook LS, Cunningham JM, De Vivo I, DeFazio A, Doherty JA, Dork T, du Bois A, Dunning AM, Durst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Velez Edwards D, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA
doi: 10.1158/1055-9965.EPI-20-0739.
Uro-Oncology
Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients
Prostate
Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI
doi: 10.1002/pros.24253